Healthcare
Live Price
Offline$381.02
+0.00% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abiomed, Inc. (ABMD) is a Healthcare stock with a market cap of $17.18B and listed on NASDAQ. The stock last traded around $381.02. Baseline metrics include revenue growth of +21.7%, EPS growth of -40.0%, a dividend yield of 0.0%. What stands out right now is revenue +21.7%, EPS -40.0%, free cash flow +12.9% with operating margin 36.1% and ROIC 17.4%. Valuation already assumes a fairly strong business story at P/E 126.8 and price/sales 16.7. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines ABMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ABMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ABMD Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ABMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$593.7M
-22.8% YoY
FY Net Income
$112.2M
-56.7% YoY
Free Cash Flow
$136.7M
-34.3% YoY
Revenue Growth
+21.7%
EPS Growth
-40.0%
Gross Margin
81.8%
Net Margin
13.2%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 1.0B | 848M | 841M | 769M | 594M |
| Gross Profit | 844M | 686M | 690M | 640M | 495M |
| Operating Income | 373M | 230M | 249M | 225M | 157M |
| EBITDA | 500M | 247M | 257M | 231M | 164M |
| Net Income | 137M | 226M | 203M | 259M | 112M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 133M | 233M | 192M | 121M | 43M |
| Total Assets | 1.7B | 1.5B | 1.2B | 1.1B | 786M |
| Total Liabilities | 170M | 165M | 151M | 117M | 97M |
| Shareholder Equity | 1.5B | 1.3B | 1.1B | 937M | 690M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -133M | -233M | -192M | -121M | -43M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
193M
-23.7% YoY
Capital Expenditures
56M
-26.9% YoY
Free Cash Flow
137M
-34.3% YoY
Key ratios
Gross Margin
81.8%
Operating Margin
36.1%
Net Margin
13.2%
ROE
9.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.